Fenretinide targets the side population in myeloma cell line NCI-H929 and potentiates the efficacy of antimyeloma with bortezomib and dexamethasone regimen. [electronic resource]
Producer: 20170613Description: 32-40 p. digitalISSN:- 1873-5835
- Antineoplastic Combined Chemotherapy Protocols -- pharmacology
- Apoptosis
- Bortezomib -- pharmacology
- Cell Line, Tumor
- Dexamethasone -- pharmacology
- Fenretinide -- pharmacology
- Humans
- Multiple Myeloma -- drug therapy
- Neoplastic Stem Cells -- drug effects
- Reactive Oxygen Species
- Side-Population Cells -- drug effects
No physical items for this record
Publication Type: Journal Article; Research Support, Non-U.S. Gov't
There are no comments on this title.
Log in to your account to post a comment.